slides · global inventory
List
Component collection for the active corpus filters, with each row opening the slide detail view.
Matching slides 110,471
Current window 80,611-80,640
Pages 3,683
Rows per page 30
Component
80,611-80,640 of 110,471
47
Includes logos of industry partners at the bottom.Kering | ESG Presentation Deck | 79 slides · Kering
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
50
The slide uses an artistic, ink-wash style illustration to represent nature and regenerative themes.Kering | ESG Presentation Deck | 79 slides · Kering
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
51
The slide uses a map-based visualization to show the geographic distribution of sustainability projects.Kering | ESG Presentation Deck | 79 slides · Kering
Conference presentation Investor relations Loop · Cost Of Inaction1 hit
59
The slide uses a numbered list format to outline four strategic pillars for human capital management.Kering | ESG Presentation Deck | 79 slides · Kering
Conference presentation Investor relations 1 hit
60
The slide uses a donut chart to represent three distinct metrics (55% Board, 55% Managers, 33% Exec Committee).Kering | ESG Presentation Deck | 79 slides · Kering
Conference presentation Investor relations 1 hit
67
Kering | ESG Presentation Deck | 79 slidesKering | ESG Presentation Deck | 79 slides · Kering
Conference presentation Investor relations 1 hit
74
The slide uses a funnel-like diagram to show how strategic goals are enabled by a core of mindset, roles, processes, and systems, supported by specific digital platforms.Kering | ESG Presentation Deck | 79 slides · Kering
Conference presentation Investor relations 1 hit
78
The slide outlines the specific financial and operational constraints for the company's share buyback program.Kering | ESG Presentation Deck | 79 slides · Kering
Conference presentation Investor relations 1 hit
04
Uses a contrast-pairs framework to position the Proteome as a more dynamic and treatable target than the Genome.Kymera | Investor Day Presentation Deck | 105 slides · Kymera
Conference presentation Investor relations Beat · Interest1 hit
05
The slide uses a 3-step process diagram to illustrate the biological mechanism of protein degradation.Kymera | Investor Day Presentation Deck | 105 slides · Kymera
Conference presentation Investor relations Beat · Interest1 hit
07
Uses a timeline-style visual to contrast established modalities with the emerging TPD field.Kymera | Investor Day Presentation Deck | 105 slides · Kymera
Conference presentation Investor relations Beat · InterestLoop · Logic Chain1 hit
11
The slide uses a bulleted list to highlight key company attributes, including their focus on Targeted Protein Degradation (TPD).Kymera | Investor Day Presentation Deck | 105 slides · Kymera
Conference presentation Investor relations Beat · DesireLoop · Logic Chain1 hit
16
Kymera | Investor Day Presentation Deck | 105 slidesKymera | Investor Day Presentation Deck | 105 slides · Kymera
Conference presentation Investor relations Beat · DesireLoop · Logic Chain1 hit
18
Kymera | Investor Day Presentation Deck | 105 slidesKymera | Investor Day Presentation Deck | 105 slides · Kymera
Conference presentation Investor relations Beat · DesireLoop · Logic Chain1 hit
20
The slide uses a biological pathway diagram to illustrate the Myddosome complex and the specific advantage of a degrader over an inhibitor.Kymera | Investor Day Presentation Deck | 105 slides · Kymera
Conference presentation Investor relations Beat · DesireLoop · Logic Chain1 hit
23
Data source: Alavi et al., Society for Investigative Dermatology Annual Meeting, 2021.Kymera | Investor Day Presentation Deck | 105 slides · Kymera
Conference presentation Investor relations 1 hit
24
The left chart is a volcano plot showing selectivity; the right chart is a dose-response curve comparing the degrader to a kinase inhibitor.Kymera | Investor Day Presentation Deck | 105 slides · Kymera
Conference presentation Investor relations 1 hit
26
The slide outlines a clinical trial methodology involving healthy volunteers (HV) and patients across SAD and MAD cohorts.Kymera | Investor Day Presentation Deck | 105 slides · Kymera
Conference presentation Investor relations 1 hit
29
The slide uses a process flow diagram to explain the experimental procedure.Kymera | Investor Day Presentation Deck | 105 slides · Kymera
Conference presentation Investor relations 1 hit
32
SAD = Single Ascending Dose; AE = Adverse Event; SAE = Serious Adverse Event.Kymera | Investor Day Presentation Deck | 105 slides · Kymera
Conference presentation Investor relations 1 hit
33
The slide compares Day 1 and Day 14 PK profiles, highlighting the accumulation and steady-state achievement.Kymera | Investor Day Presentation Deck | 105 slides · Kymera
Conference presentation Investor relations 1 hit
34
Data beyond day 14 is noted as pending.Kymera | Investor Day Presentation Deck | 105 slides · Kymera
Conference presentation Investor relations 1 hit
38
Data presented at Kymera R&D Day 2021. LLOQ = Lower Limit of Quantitation.Kymera | Investor Day Presentation Deck | 105 slides · Kymera
Conference presentation Investor relations 1 hit
41
The table details specific adverse events (Headache, Palpitations, Nausea) with subject counts, severity, and cohort distribution.Kymera | Investor Day Presentation Deck | 105 slides · Kymera
Conference presentation Investor relations 1 hit
46
The slide uses a grid layout to map drug assets against therapeutic areas (Dermatology, Respiratory, GI, Rheumatology, Hematology, Neurology, Oncology) and color-coded mechanisms of action.Kymera | Investor Day Presentation Deck | 105 slides · Kymera
Conference presentation Investor relations 1 hit
48
Includes a biological pathway diagram and three charts demonstrating efficacy in inhibiting pNFkB, cytokines, and IRAK4 degradation.Kymera | Investor Day Presentation Deck | 105 slides · Kymera
Conference presentation Investor relations 1 hit
50
The slide illustrates a biological pathway diagram showing how IRAKiMiDs degrade both IRAK4 and IMiD substrates to inhibit proliferation and survival in cancer cells.Kymera | Investor Day Presentation Deck | 105 slides · Kymera
Conference presentation Investor relations 1 hit
51
The slide uses a structured layout to contrast patient numbers with clinical disease characteristics.Kymera | Investor Day Presentation Deck | 105 slides · Kymera
Conference presentation Investor relations 1 hit
55
The diagram illustrates a multi-arm clinical trial design with dose escalation (DL1, DL2, DLx) leading to MTD/RP2D expansion cohorts for various indications, including combination therapy arms.Kymera | Investor Day Presentation Deck | 105 slides · Kymera
Conference presentation Investor relations 1 hit
60
The slide uses a central column to highlight patient numbers (US and ROW) for four specific disease indications, with clinical rationale on the right.Kymera | Investor Day Presentation Deck | 105 slides · Kymera
Conference presentation Investor relations 1 hit